News and Announcements
BioGenesis Australia signs China distribution deal for Algae products
- Published July 30, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Genesis Co Pty Ltd – trading as “BioGenesis Australia” produces the highest quality, natural 100% Australian grown health products (Chlorella, Spirulina and Super Greens).
BioGenesis is the only Australian Chlorella and Spirulina producer with an “Australia Made Australian Grown” license (No. 9298), and a full food manufacturing licence and accredited facility.
BioGenesis is revenue positive and now selling its product range through online and retail channels, in Australia, the USA, Indonesia, Singapore, Canada, Brazil, Korea and Japan and has just signed an agreement to launch into China through a major international buying group across over 200 distribution points.
The BioGenesis algae production facility is located in Bowen, North Queensland where algae and natural grass products are grown for global health food markets. This region, with its pristine natural water sources, warm temperatures and high solar radiance, provide ideal conditions for high quality, reliable year-round production.
BioGenesis is currently seeking A$500k to support growth over the next 12 months. This represents a limited opportunity to purchase shares in a business that is on its way to becoming a major player in algae products globally.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
